Not Yet RecruitingNCT06854029
Long-acting versus daily medicines for HIV prevention and opioid use in prisons
About this title
NOTRE: Optimizing Long-Acting Pre-Exposure Prophylaxis and Medications for Opioid Use Disorder Interventions in Carceral Settings
Read the official source — NCT06854029Medication studyAges 18+United StatesAddiction
Understand this study
Who could participate?
Listed age limits: from 18 years.
- Listed locations
- DurhamSee all locations and recruitment
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
What to know before participating
A point to clarify
This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?
Things to check before joining
Study start dateEstimated: September 1, 2026
- Recruitment status
- Not Yet Recruiting
- Enrollment listed in the registry
- 450
- Sponsor
- Duke University
- Sponsor type
- University
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
- Locations
- United States
- Age range
- Over 18 Years
- Official registry ID
- NCT06854029
- Official title
Show the full official title
Optimizing Long-Acting Pre-Exposure Prophylaxis and Medications for Opioid Use Disorder Interventions in Carceral Settings
Recruitment & locations
Not yet recruitingThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Durham
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is Duke University, a university.
Does this study involve medication?
Yes. The study involves medication, including Cabotegravir Injection, Cabotegravir Pill, Buprenorphine injection and Buprenorphine Pill.
Who can participate?
Listed age limits: from 18 years.
Is this study still recruiting?
The registry lists this study as not yet recruiting.
